BI 765063 is currently being evaluated in a Phase 1 clinical trial conducted in patients with advanced solid tumors. The ongoing Phase 1 study is a dose finding study of the myeloid checkpoint inhibitor BI 765063 administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a T lymphocyte checkpoint inhibitor. The study is conducted by
The article entitled: “Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance” (https://www.jci.org/articles/view/135528/ga) reports that the OSE’s R&D team discovered that the anti-SIRPα strategy reverses a major mechanism of resistance and escape to immunotherapy called “T-cell exclusion,” meaning that the activated T lymphocytes cannot penetrate the tumor core and remain blocked at its periphery. In in vivo models of resistance to anti-PD-1, PD-L1 or 4-1BB costimulation activators, studies demonstrated that T lymphocytes initially blocked at the tumor’s margin could penetrate efficiently into the tumor when blocking SIRPα in parallel. Crossing this barrier is associated with positive modulation of macrophage expression and secretion of chemokines allowing the penetration of T lymphocytes into the heart of the tumor.
ABOUT BI 765063
BI 765063, a monoclonal antibody antagonist of the key myeloid cell checkpoint inhibitor SIRPα selectively blocks the SIRPα/CD47 interaction and thus increases the function of myeloid cells: phagocytosis of tumor cells by macrophages and presentation of tumor antigens by dendritic cells. BI 765063 is also a selective inhibitor of SIRPα that by virtue of this specificity and lack of binding and blocking of a very similar receptor called SIRPɣ, ensures that response of T lymphocytes is retained to enable T cell-mediated tumor killing.
ABOUT OSE Immunotherapeutics
- Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (
Atalante 1) in Non-Small CellLung Cancer post checkpoint inhibitor failure.
In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in monotherapy and in combination with checkpoint inhibitor Opdivo®. - BI 765063 (OSE-172, anti-SIRPα monoclonal antibody): developed in partnership with
Boehringer Ingelheim ; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors. - FR104 (anti-CD28 monoclonal antibody): positive Phase 1 results; Phase 2-ready asset in autoimmune diseases or in transplantation.
- OSE-127 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with
Servier ; positive Phase 1 results; two independent Phase 2 planned in ulcerative colitis (OSE sponsor) and in Sjögren’s syndrome (Servier sponsor) to start in Q4 2020. - BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.
- CoVepiT: a prophylactic vaccine against COVID-19, developed using SARS-CoV-2 optimized neo-epitopes. Positive preclinical and human ex vivo results in
August 2020 , clinical trial expected to start end of 2020/early 2021.
Due to the COVID-19 crisis, accrual of new patients in the clinical trial TEDOPaM is temporarily suspended and initiation timelines for both Phase 2 trials of OSE-127 could be impacted during the coming months.
For more information:
Click and follow us on Twitter and LinkedIn
https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673
Contacts
Sylvie Détry | |
Sylvie.detry@ose-immuno.com | darren@lifescicomms.com |
+33 153 198 757 | +1 646 627 8387 |
French Media: FP2COM | |
fportejoie@fp2com.fr | chris@lifesciadvisors.com |
+33 607 768 283 | +41 79 367 6254 |
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of
These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the
Source:
2020 GlobeNewswire, Inc., source